Research progress on the treatment of inflammatory bowel disease with sphingosine-1-phosphate receptor modulators
- VernacularTitle:1-磷酸鞘氨醇受体调节剂治疗炎症性肠病的研究进展
- Author:
Xue ZENG
1
;
Hongwei YI
1
Author Information
1. Dept. of Pharmacology，School of Medicine，Southeast University，Nanjing 210009，China
- Publication Type:Journal Article
- Keywords:
inflammatory bowel disease;
sphingosine-1-phosphate receptor modulators;
sphingosine-1-phosphate;
Ozanimod
- From:
China Pharmacy
2025;36(7):881-886
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease （IBD）， a chronic gastrointestinal inflammatory disorder， is currently limited by conventional therapies due to its lack of specificity and pronounced drug resistance. Sphingosine-1-phosphate receptor （S1PR） modulators， as novel precision therapeutic agents， demonstrate promising efficacy in IBD treatment. This review synthesizes the mechanistic insights and recent advances in the treatment of IBD with S1PR. Our analysis reveals that S1PR modulators suppress intestinal inflammatory responses through three core mechanisms: regulating lymphocyte migration， inducing receptor degradation， and exerting subtype-specific S1PR modulation. Currently， Ozanimod and Etrasimod have been approved for IBD treatment， while Amiselimod， KRP-203， Fingolimod and Ceralifimod are not approved for clinical use， but have shown great potential for IBD disease.
